Martinb Brenner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer. An article in Nature.com recently said that: The paramount achievement in cancer treatment in the last decade has undoubtedly been the introduction of T cell targeted immunomodulators blocking the immune checkpoints CTLA-4 and PD1 or PDL1… Anti-PD1/PDL1 antibodies have become some of the most widely prescribed anticancer therapies. T-cell-targeted immunomodulators are now used as single agents or in combination with che

United statesTom isettMartinb brennerJames allisonKen kovanDror haratsTasuku honjoAmerican society of clinical oncologyContract manufacturing organizationAdamis pharmaceuticals corporationBiovaxys technologyPreclinical programFn media groupBiovaxys technology corpEuropean unionVaccine platform biovaxys technology corp